Customize your JAMA Network experience by selecting one or more topics from the list below.
In Reply We thank Hersh and colleagues for their comments regarding our recent investigation on dental opioid use in adolescents and young adults,1 and also for their multiple contributions in this area. We agree that most of the dental opioid prescriptions documented in our study were likely to come from oral surgeons who possess either doctor of dental medicine or doctor of dental surgery degrees and perform the vast majority of third molar extractions, the procedure most likely to be driving the high frequency of opioid prescriptions. We opted to include general surgeon–oral/maxillofacial specialists as a health care provider category (composing 2.4% of first prescribers of opioids) to capture all health care provider types that might be performing dental procedures, but we acknowledge that oral surgeons generally fall into the doctor of dental medicine/doctor of dental surgery category.
We also agree that third molar extractions are painful procedures and that nonsteroidal anti-inflammatory drugs and acetaminophen should be used as first-line therapy, as suggested recently in the overview of systematic reviews published by Moore and colleagues.2 However, given the high likelihood of subsequent use, abuse, and diversion, especially in this vulnerable age range, we disagree that 20 opioid pills should be prescribed routinely to all patients under the premise that a small proportion of patients might wind up needing them. Although the inability to predict the need for postoperative opioids certainly poses some challenges, creative solutions that emphasize judicious opioid prescribing are needed, as is heightened scrutiny of the need for the extractions that are driving the opioids in the first place.
Finally, we noticed a methodologic error relating to our unexposed cohort. Because this cohort, by definition, could not have received a subsequent opioid prescription from a dental clinician in 2015, an immortal time bias was introduced, which deflates the apparent risk of subsequent use in this cohort. A revised estimate of new persistent use in the unexposed cohort of 0.111% is not meaningfully different than the original estimate of 0.1%, and the absolute risk difference between the exposed and unexposed cohorts remains 6.8%. We have requested a correction of the published article to add discussion of this bias to the Limitations section.3
Corresponding Author: Alan R. Schroeder, MD, Division of Hospital Medicine, Department of Pediatrics, Stanford University School of Medicine, 300 Pasteur Dr, MC 5776, Stanford, CA 94305 (firstname.lastname@example.org).
Published Online: May 20, 2019. doi:10.1001/jamainternmed.2019.0213
Conflict of Interest Disclosures: None reported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Schroeder AR, Newman TB, Park KT. Dangers of Opioid Prescribing for Young Adults After Dental Procedures—Reply. JAMA Intern Med. Published online May 20, 2019179(7):998. doi:10.1001/jamainternmed.2019.0213
Create a personal account or sign in to: